RecruitingB-cell Non Hodgkin Lymphoma

A Study of ARC-02 in B-cell NHL

Eligible age

18+ yrs

Accepts

All genders

Locations

7 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02.

Sponsor: Taiho Oncology, Inc.

✓ 1. A documented diagnosis of B-cell Non- Hodgkin Lymphoma (NHL) per 2016 World Health Organization criteria and disease requiring treatment:
✓ 1. Follicular lymphoma (FL), Grades 1 through 3B
✓ 2. Marginal zone lymphoma (MZL)
✓ 3. Mantle cell lymphoma (MCL)
✓ 4. Diffuse large B-cell lymphoma (DLBCL)
✓ 5. Other B-cell NHL
✓ 2. Measurable disease.
✓ 3. Received at least 2 prior lines of systemic therapies and not eligible to receive additional standard of care therapies.

✕ 1. Receiving an investigational product or participating in any other type of medical research judged not to be compatible with this study.
✕ 2. Grade \> 1 neuropathy
✕ 3. History of interstitial lung disease (ILD)/pneumonitis requiring treatment or any evidence of active ILD/pneumonitis.
✕ 4. Use of:
✕ 1. Chemotherapy, radiotherapy, small molecule, investigational, and biologic agents (including CD79b-directed agents) within 28 days (or at least 5 half-lives, whichever is shorter), prior to the first dose of the study intervention.
✕ 2. Any live or live-attenuated vaccine within 28 days before the first dose of the study intervention.
✕ 5. Ongoing clinically relevant toxicity from prior anticancer therapy that has not resolved to Grade ≤ 2 (neutropenia) or Grade ≤ 1 (thrombocytopenia or nonhematologic toxicities), with the exception of alopecia.

Los Angeles

Louisville

Charlotte

Richmond

Spokane

Milwaukee

Source: ClinicalTrials.gov · NCT07691606 · last updated 2026-07-28